Document is current
Any future updates will be listed below
-
Authors
Narendran, Siddharth
Pereira, Felipe http://orcid.org/0000-0001-8884-2816
Yerramothu, Praveen
Apicella, Ivana
Wang, Shao-bin
Ambati, Kameshwari
Hirahara, Shuichiro
Kim, Younghee
Ambati, Meenakshi
Ambati, Vidya L.
Huang, Peirong
Varshney, Akhil
Nagasaka, Yosuke
Fukuda, Shinichi
Baker, Kirstie L.
Marion, Kenneth M. http://orcid.org/0000-0003-1275-5729
Deussing, Jan M.
Sadda, Srinivas R.
Gelfand, Bradley D.
Ambati, Jayakrishna
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01EY028027, R01EY29799, R01EY031039)
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
- License Information
-
More Information
Article History
Received: 18 October 2020
Revised: 8 February 2021
Accepted: 9 February 2021
First Online: 14 April 2021
Competing interests
: J.A. is a co-founder of iVeena Holdings, iVeena Delivery Systems, and Inflammasome Therapeutics, and has been a consultant for Allergan, Biogen, Boehringer-Ingelheim, Immunovant, Janssen, Olix Pharmaceuticals, Retinal Solutions, and Saksin LifeSciences unrelated to this work. J.A. and B.D.G. are co-founders of DiceRx. J.A., B.D.G., S.N., K.A., S.W., I.A., M.A., and F.P. are named as inventors on patent applications filed by the University of Virginia or the University of Kentucky. S.R.S. has been a consultant for 4DMT, Allergan, Amgen, Centervue, Heidelberg, Roche/Genentech, Novartis, Optos, Regeneron, and Thrombogenics and has received research funding from Carl Zeiss Meditec, all unrelated to this work.
